Pre- and Post-analytical Factors in Biomarker Discovery

Klont, Frank; Horvatovich, Péter; Govorukhina, Natalia; Bischoff, Rainer

doi:10.1007/978-1-4939-9164-8_1

Cited by 7 publications

(6 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to solve these misrepresentations, some considerations should be taken. In the initial phases (discovery) of the biomarker pipeline the aim will be to have the most balanced and less variable group of patients in order to avoid side effects, while in late phases (clinical) the assessment would be multicentric, prospective and including a wide range of patients covering the heterogeneity of the disease [66].…”

Section: Discussionmentioning

confidence: 99%

Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis

Rubia

Martínez‐García

Dittmar

et al. 2020

JCM

View full text Add to dashboard Cite

Endometrial cancer (EC) is the sixth most common cancer in women worldwide and its mortality is directly associated with the presence of poor prognostic factors driving tumor recurrence. Stratification systems are based on few molecular, and mostly clinical and pathological parameters, but these systems remain inaccurate. Therefore, identifying prognostic EC biomarkers is crucial for improving risk assessment pre- and postoperatively and to guide treatment decisions. This systematic review gathers all protein biomarkers associated with clinical prognostic factors of EC, recurrence and survival. Relevant studies were identified by searching the PubMed database from 1991 to February 2020. A total number of 398 studies matched our criteria, which compiled 255 proteins associated with the prognosis of EC. MUC16, ESR1, PGR, TP53, WFDC2, MKI67, ERBB2, L1CAM, CDH1, PTEN and MMR proteins are the most validated biomarkers. On the basis of our meta-analysis ESR1, TP53 and WFDC2 showed potential usefulness for predicting overall survival in EC. Limitations of the published studies in terms of appropriate study design, lack of high-throughput measurements, and statistical deficiencies are highlighted, and new approaches and perspectives for the identification and validation of clinically valuable EC prognostic biomarkers are discussed.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis

Rubia

Martínez‐García

Dittmar

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…As circulating biomarkers were measured in pragmatically collected blood samples in a randomized trial, we cannot rule out the potential for differential preanalytical sample handling or sample degradation during storage, which may have biased our result. 39 We did not have measurements of hemoglobin and could not adjust for anemia.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

Oda

Hara

Toyama

et al. 2021

Kidney International Reports

View full text Add to dashboard Cite

Introduction Several circulating markers, including autoantibodies to erythropoietin receptor (anti-EPOR antibodies), have been identified as useful biomarkers in predicting diabetic kidney disease progression. However, a direct comparison of their utility is lacking. We aimed to validate and to compare the prognostic value of anti-EPOR antibodies with that of other known biomarkers, using the ADVANCE trial and its long-term follow-up, ADVANCE-ON, cohorts. Methods In this nested case-control study from the ADVANCE trial cohort, we included 165 case participants who had the composite kidney outcome (renal replacement therapy, renal death, or doubling of serum creatinine to ≥200 μmol/l) and 330 matched controls. We compared the associations of baseline plasma levels of anti-EPOR antibodies, tumor necrosis factor receptor (TNFR)-1 and -2, and bone morphogenetic protein (BMP)-7 with kidney outcomes. Results Cases had higher baseline plasma levels of anti-EPOR antibodies than controls (median 1.7 vs. 0.6 enzyme-linked immunosorbent assay unit, P < 0.001). Higher levels of anti-EPOR antibodies were associated with an increased risk of kidney outcome (odds ratio 2.16 [95% confidence interval 1.51, 3.08], per 1 SD of log-transformed levels) after adjusting for conventional markers. Elevated circulating TNFR1 and TNFR2 levels, and lower BMP-7 levels at baseline, were associated with poor kidney outcome (odds ratios 2.06 [1.29, 3.30], 1.66 [1.13, 2.43], and 0.45 [0.32, 0.65], respectively). The addition of anti-EPOR antibodies into the model improved the prediction of kidney outcome, regardless of other biomarkers. Conclusion Anti-EPOR antibodies provide a promising biomarker, as with TNFR1, TNFR2, and BMP-7, in predicting kidney disease progression in people with type 2 diabetes mellitus.

show abstract

“…Briefly, the blood samples (3–4 ml) were collected into BD Vacutainer Plus plastic serum tubes that containing increased silica act clot activator and silicone-coated interior (Becton Dickinson, Heidelberg, Germany) by trained phlebotomists. The blood samples were collected and processed in accordance with the established protocol for sample collection as outlined by the International Society for Biological and Environmental Repositories (ISBER) Best Practices for Repositories, Collection, Storage and Retrieval of Human Biological Materials for Research ( Klont et al, 2019 ; Vaught & Henderson, 2011 ). Upon processing of the blood samples, the serum samples were aliquoted into 300 µl portions and stored at −80 °C until further use.…”

Section: Methodsmentioning

confidence: 99%

Comparative sera proteomics analysis of differentially expressed proteins in oral squamous cell carcinoma

Wong

Ramanathan

Yuen

et al. 2021

PeerJ

View full text Add to dashboard Cite

Background Oral squamous cell carcinoma (OSCC) has increased in incidence from 1990 to 2017, especially in South and Southeast Asia. It is often diagnosed at an advanced stage with a poor prognosis. Therefore, early detection of OSCC is essential to improve the prognosis of OSCC. This study aims to identify the differentially expressed serum proteins as potential biomarkers for oral squamous cell carcinoma (OSCC). Methods Comparative proteomics profiling of serum samples from OSCC patients, oral potentially malignant disorder (OPMD) patients, and healthy individuals were performed using two-dimensional gel electrophoresis (2-DE) coupled with mass spectrometry (MS) (n = 60) and bioinformatics analysis. The enzyme-linked immunosorbent assay (ELISA) (n = 120) and immunohistochemistry (IHC) (n = 70) were used to confirm our findings. Results The 2-DE analysis revealed that 20 differentially expressed proteins were detected in OPMD and OSCC (p < 0.05). Bioinformatics analysis indicated that the activation of classical complement, liver X receptor/retinoid X receptor (LXR/RXR) activation, and acute phase response signaling pathway are associated with the development and progression of OSCC. Most of the detected proteins are acute-phase proteins and were related to inflammation and immune responses, including apolipoprotein A-I (APOA1), complement C3 (C3), clusterin (CLU), and haptoglobin (HP). The expression levels of CLU and HP in ELISA are consistent with the findings from the 2-DE analysis, except for the mean serum level of HP in OPMD, whereby it was slightly higher than that in control. IHC results demonstrated that CLU and HP are significantly decreased in OSCC tissues. Conclusion Decreased expression of CLU and HP could serve as complementary biomarkers of OSCC. These proteins may assist in predicting the outcomes of OSCC patients. However, a larger cohort is needed for further investigation.

show abstract

Pre- and Post-analytical Factors in Biomarker Discovery

Cited by 7 publications

References 59 publications

Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis

Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis

Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

Comparative sera proteomics analysis of differentially expressed proteins in oral squamous cell carcinoma

Contact Info

Product

Resources

About